Lilly(Eli) & Company
NYSE: LLY
$795.64
-$0.03 (0.0%)
Real Time Data Delayed 15 Min.
LLY Articles
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
Published:
Last Updated:
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.
Published:
Last Updated:
Eli Lilly released a mixed fourth-quarter earnings report and offered full-year guidance before the markets opened on Tuesday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of some of the major companies reporting on Tuesday, including Apple and two other Dow stocks.
Published:
Last Updated:
The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly down.
Published:
Last Updated:
Trump said last week that companies in the health care sector are “getting away with murder,” and that something had to change. The sector has pulled back slightly since then, but there are still...
Published:
Last Updated:
This acquisition not only will enhance Eli Lilly's existing portfolio in pain management for migraine, but it also adds a potential near-term launch to its late-stage pipeline.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday include American Express, JPMorgan, Netflix, Nordstrom and Twitter.
Published:
Last Updated:
The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
Published:
Last Updated:
These are five top new picks that the JPMorgan team likes this month. All make good sense for growth portfolios.
Published:
Last Updated:
The December 15 short interest data have been compared with the previous figures, and short interest increased in most of these selected pharmaceutical stocks.
Published:
Last Updated:
These are stocks that make good sense for investors looking to add to their overall equity holdings. They are all trading well below their 52-week highs and should be attracting substantial...
Published:
Last Updated:
For those looking to generate income, equities remain one of the best resources, and these five look like long-term winners.
Published:
Last Updated:
With the top pharmaceutical stocks trailing the market by a large margin, they are starting to look very attractive for long-term growth and income investors.
Published:
Last Updated:
In a recent research note, the analysts at Merrill Lynch make a big move by removing two blue chips from the firm's well-respected US 1 list of stocks to buy.
Published:
Last Updated: